Ensysce Biosciences, Inc. Share Price & Technical Analysis
ENSC · $0.25 (0.00%)
Healthcare / Biotechnology
$0.25
0.00%
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) …
Price chart
Seasonality
Jun has 1 positive and 2 negative years (last 5 years shown)
0% return in Jun, -12% avg return in past 3 year Jun month.
-82% return in 2026, -111% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -22% | -14% | 0% | -20% | -25% | 0% | – | – | – | – | – | – | -82% |
| 25 | -17% | -21% | -53% | 15% | -29% | 0% | -5% | 0% | 20% | -4% | -14% | -47% | -154% |
| 24 | 59% | -40% | -14% | -24% | -3% | -12% | -9% | -13% | -40% | 139% | -20% | 5% | 26% |
| 23 | -15% | -30% | -17% | -28% | -33% | -24% | -3% | -11% | -27% | -32% | 20% | -7% | -206% |
| 22 | -63% | -36% | 2% | 2% | -51% | 38% | -23% | -15% | -47% | -26% | -8% | -75% | -304% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.66M
P/E ratio
—
52W high
$2.75
52W low
$0.23
Volume
11,16,728
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Ensysce Biosciences, Inc. share price today?
- Ensysce Biosciences, Inc. (ENSC) last traded around $0.25 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ENSC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ENSC. Download the app for real-time alerts.
- How can I analyze Ensysce Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.